Apart from its hematopoietic function, erythropoietin (Epo) exerts neuroprotective activity upon reduced oxygenation or ischemia of brain, retina, and spinal cord. To examine whether Epo has an impact on the retrograde degeneration of retinal ganglion cells (RGCs) following optic nerve transection in vivo, we made use of our transgenic mouse line tg21 that constitutively expresses human Epo preferentially in neuronal cells without inducing polycythemia. We show that the tg21 retina expresses human Epo and that RGCs in this mouse line carry the Epo receptor. Upon axotomy, the RGCs of Epo transgenic tg21 mice were protected against degeneration, as compared with wild-type control animals. Western blot analysis revealed decreased phosphorylation levels of STAT-5 and reduced expression of Bcl-X L in RGCs of axotomized tg21 animals, suggesting that the corresponding pathways are not crucial for Epo's neuroprotective activity. Increased phosphorylation levels of ERK-1/-2 and Akt, as well as decreased caspase-3 activity, however, were observed in injured tg21 retinae. Injection of selective inhibitors of ERK-1/-2 (PD98059) or Akt (Wortmannin) pathways into the vitreous space revealed that transgenic Epo protected the RGCs by a pathway involving ERK-1/-2 but not Akt. In view that axotomy-induced degeneration of RGC occurs slowly, and considering the earlier data on the safety and efficacy of Epo in human stroke patients, we predict the clinical implementation of recombinant human Epo not only in patients with acute ischemic stroke, but also with more delayed degenerative neurological diseases.
treatment, but also under more delayed degenerative neurological conditions, such as amyotrophic lateral sclerosis, Parkinson's and Alzheimer's disease. In view that Epo is routinely administered in anaemic patients with renal failure (6, 7) , this drug is considered to be safe in humans (5) .
In vitro studies using primary motor neurons and neuronal-glial cultures submitted to serum withdrawal or treated with kainate provided further insight into the neuroprotective action of Epo. In vitro, Epo activates Janus-tyrosine kinase (JAK)-2, which is linked with the Epo receptor via its Box-1 motif (for review, see ref. 8 ). JAK-2 in turn phosphorylates and thereby activates downstream signaling factors, such as the mitogen-activated protein (MAP) kinases extracellular-regulated kinase (ERK)-1/-2 (3), phosphatidyl inositol 3 kinase (PI3K)/Akt (3, 9) , Jun kinase (JNK) (10, 11) , and signal transducers and activators of transcription (STAT)-5 (3, 12) . STAT-5 then stimulates mitochondrial anti-apoptotic proteins, such as Bcl-X L (13) , and consecutively inhibits cytochrome c-dependent caspases (9, 13) .
In the present study, we investigated the in vivo action of Epo in delayed neuronal degeneration, making use of a transgenic mouse line (termed tg21) constitutively expressing human Epo in the central nervous system (CNS) under the control of the human platelet-derived growth factor (PDGF) B-chain promoter (14, 15) that we submitted to optic nerve transection. Note that the plasma hematocrit was identical in wild-type and tg21 animals (15) . Optic nerve transection is a very reproducible in vivo model of CNS neuronal degeneration (16, 17) . Ontogenetically, retinal ganglion cells (RGCs) are CNS-derived neurons that due to their accessibility outside the cranial cavity offer themselves in an almost exemplary manner to study cell death mechanisms and neuroprotection. We have recently shown that this model may successfully be transferred to mice (18, 19) .
MATERIALS AND METHODS

Retrograde labeling of RGCs
Experiments were performed in accordance to the Swiss guidelines for the care and use of laboratory animals and approved by local government authorities (Kantonales Veterinäramt Zürich). Male tg21 mice, aged 12 wk, expressing human Epo under control of a human PDGF Bchain promoter (HindIII-XmnI fragment; see refs. 14, 15) or wild-type control animals were anesthetized with 1% halothane (30% O 2 , remainder N 2 O) and placed in a stereotactic frame. A bur hole was drilled into the pericranium overlying the superior colliculi (0.7 mm lateral to sagittal suture, 3 mm posterior to bregma). For retrograde labeling of RGCs, a Hamilton syringe was inserted 2.0 mm beneath the brain surface, and 0.7 µl of fluorogold (Fluorochrome, Denver, CO) were injected stereotactically into both superior colliculi (infusion rate 0.7 µl/min). After infusion, the injection needle remained inside the brain for 2 min to prevent fluorogold diffusion along the needle track. The syringe was then withdrawn, and wounds were carefully closed with a suture.
Optic nerve transection
Three days after axotomy, mice were reanesthetized with 1% halothane. After skin incision close to the superior orbital rim, the right orbita was opened, leaving the supraorbital vein intact, and the lacrimal gland was resected subtotally. After spreading the superior extraocular muscles, the right optic nerve was transected under microscopical control ~0.5 mm distant to the posterior pole of the eye, taking care not to damage retinal blood vessels. The wounds were sutured, and retinal blood supply was verified by fundoscopy.
Tissue processing
Fourteen days after axotomy, mice were killed by an overdose of chloral hydrate, and both eyes were removed. Retinae were dissected, flat-mounted on glass slides, and fixed in 4% paraformaldehyde (PFA)/0.1 M phosphate buffered saline (PBS) for 30 min (n=5-6 animals/strain). Retinal flat mounts were evaluated by one of the investigators blinded for the experimental conditions (Ü.K.) by fluorescence microscopy using appropriate filters. RGC densities were determined by counting tracer-labeled RGCs in 12 distinct areas of 62,500 µm 2 each (three areas per retinal quadrant at 1/6, 3/6, and 5/6 of the retinal radius, respectively) both on the lesioned and on the contralateral nonlesioned side, subsequently calculating mean values over the three eccentricities analyzed as well as the whole retina. Additional retinae were used for Western blots (n=5 animals/strain).
Western blots
Tissue samples were dissected, complemented with lysis buffer, homogenized, and centrifuged, and supernatants were used for sodium dodecylsulfate-PAGE (SDS-PAGE). Blots were carried out with protein samples pooled from all animals belonging to the same group. Equal amounts of protein were diluted in 6× sample buffer, boiled, and loaded on polyacrylamide gels. Proteins were then transferred onto PVDF membranes. Membranes were dried overnight, incubated in blocking solution, and immersed with monoclonal mouse anti-diphospho-ERK-1/-2 (M8159; Sigma, St. Louis, MO), polyclonal rabbit anti-phospho Akt (No. 9271; Cell Signaling, Allschwil, Switzerland), monoclonal mouse anti-diphospho-JNK (J4750; Sigma), polyclonal rabbit anti-JAK-2 (C20, sc-294; Santa Cruz, Nunningen, Switzerland), polyclonal rabbit anti-phospho-STAT-5 (No. 9351; Cell Signaling), polyclonal rabbit anti-Bcl-X (No. 610212; BD Biosciences, Basle, Switzerland), or polyclonal rabbit anti-activated caspase-3 (CM1; BD Biosciences), each diluted 1:500 in 0.1% Tween 20/0.1 M Tris-buffered saline (TBS). Membranes were rinsed, incubated in peroxidase-coupled, secondary antibodies (Santa Cruz), diluted 1:2000 in 0.1% Tween 20/0.1 M TBS, washed, immersed in enhanced chemoluminescence (ECL) solution, and exposed to ECL-Hyperfilm (Amersham, Braunschweig, Germany). Protein loading was controlled in additional blots using a monoclonal mouse antibody against anti-β-actin (A5316; Sigma). All blots were performed at least three times in order to confirm the reproducibility of the data. Protein levels were analyzed densitometrically, corrected with values determined on anti-β-actin blots, and finally expressed as relative values compared with nonlesioned retinae of wild-type mice.
Inhibition of ERK-1/2 and phosphatidyl inositol-3′ kinase (PI3K)/Akt pathways
By means of a glass microelectrode with a tip outer diameter of 50 µm, 0.5 µl of either 1) 100% DMSO; 2) the MAPK/ERK kinase-1 (MEK-1) inhibitor PD98059 (50 mM; New England Biolabs GmbH, Schwalbach, Germany), dissolved in 100% DMSO; or 3) the phosphatidyl inositol-3′ kinase (PI3K)/Akt inhibitor Wortmannin (0.1 mM; Sigma), dissolved in 100% DMSO, was carefully injected into the vitreous space, puncturing the eye at the cornea-sclera junction (n=3-4 tg21 animals/group). The injections were done at days 0, 4, 7, and 10 after optic nerve transection following exactly the same protocol as described above. This procedure has previously been used successfully with the same signal inhibitors at identical concentrations in order to characterize signal tranduction pathways mediating neuroprotection in RGCs (20, 21) . Animals were killed 14 days after axotomy, and their retinae were removed, flat-mounted, and evaluated microscopically.
In control experiments, repeated injections of 0.5 µl of 1) 100% DMSO; 2) 50 mM PD98059, dissolved in 100% DMSO; or 3) 0.1 mM Wortmannin, dissolved in 100% DMSO, were made into the vitreous space of nonlesioned (wild-type) mice according to the same protocol (injections at 0, 4, 7, and 10 days; n=2 animals/group). Animals were killed at 14 days after the first injection. RGC density was determined as above. These control studies revealed that the manipulations and chemicals used had no effect on RGC survival (RGC density in untreated control animals: 4152±162 RGCs/mm 2 ; in DMSO-treated animals: 4269±297/mm 2 ; in DMSO/PD98059-treated animals: 4090±381/mm 2 ; in DMSO/Wortmannin-treated animals: 4096±272/mm 2 ).
Radioimmunoassay (RIA) of retinal Epo levels
Additional animals (n=3 each for wild-type and tg21 mice) were used for Epo measurements using an 125 I-Epo-based RIA (DiaSorin, Stillwater, MN), according to previously published protocols (22) . Briefly, whole retinae were homogenized in a lysis buffer (containing 150 mM NaCl; 10 mM EDTA; 50 mM Tris-HCl; 0.25% Triton; 0.1% NP-40 and protein inhibitors) and centrifuged at 15,000 rpm for 25 min. Total protein concentrations were calculated using a bicinchoninic acid (BCA) protein assay (Pierce) reagent. The lower detection limit of our RIA was 4 U/l, the intrassay/interassay variances were <2% and <6%, respectively. All Epo measurements were performed in duplicate. Mean values were calculated for both measurements.
Immunohistochemical detection of Epo receptor
Additional animals (n=3 each for wild-type and tg21 mice) were used for Epo receptor immunohistochemistry. Eyes were removed, frozen on dry-ice, and cut on a cryostate into 20 µm sections. Sections were fixed in 4% paraformaldehyde/0.1 M PBS, washed, and immersed for 1 h in 0.1 M PBS containing 0.3% Triton (PBS-T)/10% normal goat serum. Sections were incubated overnight at 4°C with polyclonal rabbit anti-Epo receptor (H-194, sc-5624; Santa Cruz), diluted 1:100 in PBS-T. After washing, sections were incubated in secondary FITClabeled anti-rabbit antibody, stained with 4',6-diamidino-2-phenylindole (DAPI), and placed on coverslips.
Data analysis and statistics
Data were analyzed by two-tailed t tests (comparisons between 2 groups) and one-way ANOVA followed by LSD tests (comparisons between ≥3 groups) using SPSS for Windows 10.1. Results are presented as means ± SD values, with n values indicating the number of different samples analyzed. P<0.05 was considered significant.
RESULTS
The retinae of tg21 mice express human Epo
To determine whether our tg21 mouse indeed expresses human Epo in the retina, we did RIA analysis. These experiments revealed significantly elevated Epo levels in the retinae of tg21 mice, as compared with nontransgenic wild-type animals (94.4±6.6 vs. 59.5±2.1 mU Epo/mg protein). Our data confirm that in tg21 mice, increased expression of Epo occurs not only in the brain, as previously shown (15), but also in the eyes.
Epo receptor is expressed on RGCs
Immunohistochemical analysis revealed a robust expression of Epo receptor on RGCs (Fig. 1) . In contrast to Epo, expression levels of Epo receptor did not differ between wild-type and tg21 mice (Fig. 1) .
Epo protects against RGC degeneration
Stereological analysis of fluorogold-prelabeled RGCs in axotomized mice revealed that Epo markedly increased the density of surviving RGCs (see Fig. 2A-C) . While only 21.3 ± 7.6% of ganglion cells were viable at 14 days after lesioning in nontransgenic wild-type mice, as many as 61.4 ± 20.6% of cells were preserved in transgenic animals (P<0.01). Neuroprotection was similarly seen in all retinal eccentricities, both close to the posterior pole of the eye and distant to it (Fig. 2B) . Ganglion cell densities in nonlesioned retinae did not differ between wild-type and tg21 mice (Fig. 2C, 2D ).
Constitutive ERK-1/-2, Akt, and STAT-5 activities are elevated in nonlesioned retinae of tg21 mice
To elucidate signaling mechanisms mediating Epo's neuroprotective activity, we performed Western blots using retinal homogenates. Blots of nonlesioned control retinae showed that activities of ERK-1/-2, Akt, and STAT-5 were higher in tg21 than in wild-type mice (Fig. 3) . Constitutive JAK-2, JNK, Bcl-X L , and caspase-3 levels, on the other hand, did not differ between both mouse lines (Fig. 3) .
ERK-1/-2 and Akt signaling are increased, while JNK and caspase-3 signaling are decreased after axotomy in tg21 mice
In tg21 mice, ERK-1/-2 phosphorylation markedly increased after RGC axotomy (Fig. 3) . Akt phosphorylation, on the other hand, remained high after lesioning, while JNK activity mildly decreased (Fig. 3) . In wild-type mice, optic nerve transection did not induce any signaling changes, of phosphorylated Akt or of MAP kinases (Fig. 3) . Our data suggested a role of both ERK-1/-2 and Akt signaling in Epo's neuroprotective activity. Caspase-3 activity was markedly inhibited in axotomized retinae of Epo expressing, but not in those of control mice (Fig. 3) , indicating that Epo signaling converged in the inhibition of the executioner caspase-3.
JAK-2, STAT-5, and Bcl-X L signaling are attenuated after optic nerve transection in tg21 mice
Optic nerve transection markedly reduced retinal JAK-2 and Bcl-X L levels and also mildly decreased STAT-5 phosphorylation levels in tg21 mice (Fig. 3) . In nontransgenic animals, on the other hand, JAK-2 and Bcl-X L levels remained unchanged after lesioning, while STAT-5 activity markedly increased, even above levels of transgenic mice (Fig. 3) . The reduced STAT-5 and Bcl-X L signaling argues against an involvement of these pathways in Epo's neuroprotective activity, at least in the experimental paradigm and mouse line used.
Epo-induced neuroprotection in vivo is mediated by ERK-1/-2 signaling
To define whether ERK-1/-2 or Akt signaling pathways are responsible for Epo-induced neuroprotection, we locally applied the solvent DMSO with or without signal transduction inhibitors into the eye's vitreous space. While the PI3K/Akt inhibitor Wortmannin did not influence RGC survival to a major extent, inhibition of ERK-1/-2 using the MEK-1 inhibitor PD98059 completely abolished the protective effects of Epo (see Fig. 2D ). Our data imply that Epo-induced neuroprotection critically depends on the activation of the ERK-1/-2, but not of the Akt pathway.
DISCUSSION
Epo protects against RGC degeneration in vivo
Using the transgenic mouse line tg21, which expresses human Epo predominantly in the CNS, we were able to demonstrate in the RGC axotomy model that the hematopoietic growth factor Epo protects CNS neurons in vivo against delayed neuronal degeneration via ERK-1/-2 signaling. Already in the mid-1990 s, it was realized that Epo, apart from its expression in the liver and kidney, is expressed in the CNS of rodents, monkeys, and humans (23, 24) . Induction of Epo transcription takes place in an oxygen-dependent manner, via activation of hypoxiainducible factor-1 (HIF-1) (for review, see refs. 1, 25). HIF-1-induced Epo expression is involved not only in high-altitude adaptation (1), but may also mediate resistance against brain ischemia (2, 3) as well as against light-induced photoreceptor degeneration (4) . We now expand these actions showing that Epo expression in vivo is protective not only against rather rapidly progressing acute, but also against rather slowly developing subacute, neuronal injury. We provide evidence that human Epo is indeed expressed in the retinae of tg21 mice. In our RIAs, we observed an ~60% increase of total retinal Epo content, as compared with wild-type animals. Considering that Epo is secreted by neurons, we assume that this ~60% increase represents an underestimation of local Epo concentrations in the surrounding of the ganglion cells. Moreover, in view that retinal Epo acts most likely in a paracrine fashion, we consider this increase as physiologically relevant.
A great advantage of the retinotectal projection in the study of neuronal degeneration and protection is the highly coordinated signaling response induced in axotomized RGCs, resulting in the activation of executive cell death programs and leading to the loss of ~80% of RGCs within 14 days after lesioning (16, 17) . Because of the highly standardized injury pattern, the RGC model has previously been used already to assess actions of various growth factors in rats (20, 21) and mice (18, 19) . Thus, it is noteworthy that the neuroprotection efficacy of Epo in the present experiments was higher than that previously seen for classical neurotrophins, such as brain-derived neurotrophic factor (BDNF) (20) , insulin-like growth factor-I (IGF-1) (21), or glial cell line-derived neurotrophic factor (GDNF) (19) , all of which achieved RGC survival rates of <50%. This raises the question about the mechanisms underlying Epo-induced neuroprotection.
Epo modulates ERK-1/-2, PI3K/Akt, and JNK pathways in vivo
Based on in vitro studies suggesting that Epo induces a large number of signaling changes in various cell types, including alterations of MAP kinases ERK-1/-2 (3), PI3K/Akt (3, 9), JNK (10, 11), STAT-5 (3, 12), Bcl-X L (13), and caspase-3 (9, 13), we hypothesized that the pronounced rescue effects of Epo may be due to its pleiotropic actions. Yet, it remained unclear whether signaling responses previously reported in vitro were similarly relevant in vivo. Interestingly, as in earlier in vitro studies using neuronal cell cultures (3, 9), we were able to confirm in the present experiments that Epo expression indeed induced a pronounced activation of both ERK-1/-2 and Akt signaling pathways after optic nerve transection, while JNK phosphorylation was mildly reduced in axotomized tg21 mice. An inhibition of JNK phosphorylation by Epo has not been shown in neuronal cells so far. In erythropoietic precursor cells, Epo delivery increased JNK phosphorylation (10, 11) , an effect made responsible for the trophic actions of Epo. Yet, the role of JNK in the CNS differs from that in erythropoietic precursor cells, since JNK activates rather than inhibits cell death cascades in the CNS (for review, see ref. 8). Accordingly, differential effects of Epo on JNK signaling in the CNS and blood most likely represent cell-type-specific actions.
ERK-1/-2 but not PI3K/Akt is required for Epo's neuroprotective activity
In neuronal cell cultures, both ERK-1/-2 and PI3K/Akt have similarly been shown previously to contribute to neuroprotection induced by Epo, as seen after delivery of signal transduction inhibitors (3). The question arose whether both signaling cascades were also involved in Epoinduced neuroprotection in vivo. To clarify this issue, we made use of a procedure that has previously been applied successfully to unravel signal transduction mechanisms following optic nerve transection in vivo (20, 21) : injecting the MEK-1 inhibitor PD98059 and PI3K/Akt inhibitor Wortmannin directly into the eye's vitreous space. Interestingly, in our studies, only inhibition of ERK-1/-2, but not of PI3K/Akt, reversed Epo's neuroprotective activity. Thus, the mechanism of action of Epo differs from classical neurotrophins, such as BDNF, for which neuroprotection could not be abolished by MEK-1 inhibition following RGC axotomy (20) .
STAT-5 and Bcl-X L signaling are not activated after RGC axotomy in tg21 mice
While it has previously been shown that Epo stimulates the JAK-2, STAT-5, and Bcl-X L pathways in vitro (3, 8, 12, 13) , the latter signaling cascades were not activated after axotomy in tg21 mice. JAK-2 is a cytosolic protein, which binds to the Box-1 motif of Epo receptor and is thereby phosphorylated and activated, subsequently stimulating activation of 12) and, in turn, expression of the mitochondrial anti-apoptotic protein Bcl-X L (13) . It has long been believed that inhibition of programmed cell death by Epo is critically dependent on the activation of Epo receptor and, consecutively, JAK-2 (26) . Indeed in cells carrying dominant JAK-2 deletions or a biologically incompetent JAK-2, Epo was no longer effective in inhibiting apoptosis (27, 28) . On the other hand, a very recent report shows that Epo derivatives not binding to the classical homodimeric Epo receptor (such as carbamylated Epo) may still exhibit preserved neuroprotective activity, while the erythropoietic potency of such compounds is absent (29). Thus, we cannot exclude that Epo receptor/JAK-2 is not required for Epo's neuroprotective effects. Further studies are needed to prove this notion. The lack of a STAT-5 and Bcl-X L activation in axotomized RGCs argues against an involvement of STAT-5 and Bcl-X L signaling in Epo-induced neuroprotection, at least in the mouse strain and model used. Our data also suggest that Epo's neuroprotective activity is not mediated via a mitochondrial loop, but directly via cytosolic pathways.
Outlook
The neuroprotective action of Epo in the present study might open new perspectives for the treatment of subacute and more chronic neurodegenerative diseases that, similar to stroke, may also profit from Epo under clinical conditions. Neurodegenerative illnesses, such as Parkinson's and Alzheimer's disease, are extremely frequent disorders and are major causes of long-term disability and impose tremendous burdens to public health care. Unfortunately, there are no efficacious treatments available at present that allow prevention of neuronal degeneration in a causative manner. Establishing efficacious strategies in this context would not only create entirely new perspectives for neurological therapy and open hopes for millions of patients concerned, but also would have favorable socioeconomical consequences, since clinical improvements would result in reduced rehabilitation costs. The development of clinically applicable protection strategies will deserve concerted efforts in the near future, as a priority issue in clinical neurosciences. Epo is an highly attractive candidate in this context, even more so after derivatives have recently been characterized that exhibit neuroprotective but not erythropoietic action (29). Chances appear favorable that it will thus be possible to establish clinically applicable treatments. Note that optic nerve transection stimulates both ERK-1/-2 and Akt phosphorylation and inhibits caspase-3 activity and JNK phosphorylation in lesioned retinae of tg21 mice, suggesting a role of these signaling factors in Epo-induced neuroprotection. Furthermore, decreased expression levels of JAK-2 and Bcl-X L and reduced phosphorylation levels of STAT-5 in RGCs of axotomized tg21 animals indicate that the corresponding pathways are not crucial for Epo's neuroprotective activity. Co, nonlesioned control eye; As, axotomized eye. Data are mean ± SD (n=3 different samples/group), normalized with corresponding blots for β-actin, for which a representative blot is also shown. *P < 0.05 compared with nonlesioned wild-type mice; # P < 0.05 compared with axotomized tg21 mice.
